Invokana Dosage

Prior to Initiation of INVOKANA

Assess renal function before initiating INVOKANA and as clinically indicated .

In patients with volume depletion, correct this condition before initiating INVOKANA .

Recommended Dosage and Administration

Recommended Dosage in Adults and Pediatric Patients Aged 10 Years and Older with Renal Impairment

​Table 1 provides dosage recommendations for adults and pediatric patients aged 10 years and older with renal impairment, based on estimated glomerular filtration rate (eGFR).

Concomitant Use with UDP-Glucuronosyl transferase (UGT) Enzyme Inducers

When co-administering INVOKANA with an inducer of UGT (e.g., rifampin, phenytoin, phenobarbital, ritonavir), increase the dosage of INVOKANA based on renal function:

• In patients with eGFR 60 mL/min/1.73 m 2or greater, increase the dosage to 200 mg orally once daily in patients currently tolerating INVOKANA 100 mg once daily. The maximum recommended dosage of INVOKANA is 300 mg once daily.
• In patients with eGFR less than 60 mL/min/1.73 m 2, increase to a maximum recommended dosage of 200 mg orally once daily in patients currently tolerating INVOKANA 100 mg once daily.

Temporary Interruption for Surgery

​Withhold INVOKANA at least 3 days, if possible, prior to surgery or procedures associated with prolonged fasting. Resume INVOKANA when the patient is clinically stable and has resumed oral intake.